Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK2809 phase 2b study in biopsy-proven nonalcoholic steatohepatitis with fibrosis
2020-000217-32Phase 2Completed
- Sponsor
- VIKING THERAPEUTICS, INC.
- Start
- Mar 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VK2809 in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (5 arms), sponsored by VIKING THERAPEUTICS, INC. Primary endpoint: Relative change in liver fat content from baseline to Week 12. Started Mar 2020; status: completed.
02
Drugs
VK2809
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2020-000217-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000217-32.